Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Neoplasms: early-phase trial registry
12 of 24 indexed Head and Neck Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 12 currently recruiting · #686 of 28,707 conditions by registered trial count
Head and Neck Neoplasms: 24 US clinical trials tracked, 12 recruiting.
Head and Neck Neoplasms is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is University of Chicago, running 3 of these trials.
Enrollment posture brief
Registry condition head-and-neck-neoplasms
OPEN 12 | RECR 50% | LATE 3 | EARLY 15 | RANK #686 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Head and Neck Neoplasms lists 12 open slots (50% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Neoplasms is recruiting above its size-band peers.
12 of 24 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Head and Neck Neoplasms trials is spread across many organizations.
University of Chicago accounts for 3 of 24 trials (12.5%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Head and Neck Neoplasms enrolment sits around 78 participants.
Median target enrolment is 78 among the 24 trials that report a genuine target (sentinel values excluded). 13 of those (54.2%) plan for fewer than 100 participants.
-
Head and Neck Neoplasms research is mostly interventional.
21 interventional and 3 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
National Institute on Deafness and Other Communication Disorders (NIDCD)
NCT06303180
Molecular and Genomic Profiling of Head and Neck Tumors
Montefiore Medical Center
NCT00200486
Biospecimen Procurement for Head and Neck Disorders
National Cancer Institute (NCI)
NCT03429036
First in Human Study of AZD9592 in Solid Tumors
AstraZeneca
NCT05647122
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
Medical University of South Carolina
NCT05811936
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
NCT07158164
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
NCT06912087
EMST in Patients Undergoing CRT for HNCA
University of Wisconsin, Milwaukee
NCT03916809
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
NCT05420948
Head and Neck Cancer Study Project in the Geriatric Population
Brown University
NCT06998069
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT05544136
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Merck Sharp & Dohme
NCT03765918
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT06003231
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
NCT06110195
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT06237881
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
NCT03077243
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT03082534
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Cancer Institute (NCI)
NCT00923481
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
University of Iowa
NCT00721799
Image-guided Cryoablation of Head, Neck and Spine Tumors
Dana-Farber Cancer Institute
NCT02085941
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute
NCT00402545
Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck
Erimos Pharmaceuticals
NCT00057512
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Neoplasms page
24 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Head and Neck Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Chicago sponsors the most Head and Neck Neoplasms trials on record, review their full trial history before evaluating a specific study. See University of Chicago's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Neoplasms condition card totals 24 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.